Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial enrolled 118 people across several types of neuroendocrine tumours (NETs) — a group of tumours that can arise in various parts of the body and are often identified by particular chemicals they produce in the blood. All participants received a long-acting injectable medicine called pasireotide LAR 60mg. The trial was measuring whether participants' blood levels of specific tumour-related chemicals either returned to normal, or fell by more than half, after six months of treatment. Ninety participants reached the six-month point, and 22 completed the full study. The primary goal — looking at a combined group of pancreatic NET patients — could not be fully assessed because fewer patients than planned (20 out of an intended 34) could be included in that analysis. The reported data shows that, among the tumour types where enough patients were enrolled to allow analysis, the percentage who met the response target at six months varied. For gastrinoma patients, 46.2% were recorded as responders. For prolactinoma patients, 21.6% were recorded as responders. For Nelson's syndrome patients (a condition involving a particular tumour of the pituitary gland), 50% were recorded as responders. In terms of actual patient numbers, the reported data shows 5 out of 8 gastrinoma patients, 9 out of 7 prolactinoma patients (note: these figures are as submitted to ClinicalTrials.gov and appear inconsistent in the source data), and 6 out of 6 Nelson's syndrome patients met the response criteria. For other tumour types — including VIPoma and glucagonoma — the reported responder rate was 0%, and some tumour types had too few participants to be formally analysed at all. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 2 Pancreatic Cancer Trial, Terminated
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- You must be at least 18 years old (male or female)
- You must have a rare type of tumour that comes from hormone-producing tissues, such as tumours of the pancreas, pituitary gland, Nelson syndrome, or a tumour that produces a hormone called ACTH from an unusual location in the body (confirm with trial site)
- You must have already tried standard treatments that did not work, or there must be no standard treatment available for your condition
- You must be willing and able to sign a consent form agreeing to take part
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- You cannot join if you currently have an active gallbladder disease or condition
- You cannot join if you are currently receiving or planning to receive any cancer treatment or a therapy called interferon
- You cannot join if your diabetes is not well controlled
- You cannot join if you are pregnant, breastfeeding, or are able to become pregnant and are not using a medically approved form of contraception
Important: There may be additional eligibility requirements not listed here. Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Trial contact details on record
Principal Investigator: Novartis Pharmaceuticals, Novartis Pharmaceuticals
Australian sites
This trial is not accepting new participants. These are the contact details ClinicalTrials.gov holds for it, kept here for reference. They are not an invitation to enrol, and the sites listed may no longer be running this trial.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial was run
These are the locations recorded on the registry, including 2 in Australia. They are a historical record: this trial is not enrolling, so they are not places you can join it.
Primary endpoints
Percentage of Responders at Month 6 - Pooled Pancreatic NETs (PNETs)
Other options
Data last synced from ClinicalTrials.gov: 17 August 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.